Complete sequence of p53 gene in 20 patients with lung cancer: Comparison with chemosensitivity and immunohistochemistry

Medical Oncology

Volumn 15, Issue 4, 1998, Pages 255-261

  Brattström, Daniel ^a   Bergqvist, Michael ^a   Lamberg, Kristina ^a   Kraaz, Wolfgang ^a   Scheibenflug, Lena ^a   Gustafsson, Gunnar ^a   Inganäs, Mats ^b   Wagenius, Gunnar ^a   Brodin, Ola ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

ALFexpress; Bax; Bcl 2; cDNA sequencing; Drug resistance; Immunohistochemistry; Mutation; Non small cell lung cancer; NSCLC; p53

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; DNA SEQUENCE; DRUG RESISTANCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MICROFLUOROMETRY; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL;

EID: 0032456326     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787209     Document Type: Article

References (29)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
2. Takahashi T et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
3. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comments]. Science 1994; 265: 346-355.
4. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994; 13: 3496-3504.
5. Williams C et al. Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem 1998; 44: 455-462.
6. Kawasaki M et al. p53 immunostaining predicts chemosensitivity in non-small cell lung cancer: a preliminary report. Cancer J Sci Am 1996; 2: 217.
7. Rusch V et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-5042.
8. Fujiwara T et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-2291.
9. Elledge RM. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? [editorial]. J Natl Cancer Inst 1996; 88: 141-143.
10. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
11. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
12. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 3173-3178.
13. Marx D et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17: 2233-2240.
14. Apotinario RM et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997; 15: 2456-2466.
15. Sjogren S et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-182.
16. Larsson R, Nygren P. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 1990; 46: 67-72.
17. Nygren P et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphob-lastic leukemia. Leukemia 1992; 6: 1121-1128.
18. Cattoretti G et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections [see comments]. J Pathol 1993; 171: 83-98.
19. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-244.
20. Cariello NF, Beroud C, Soussi T. Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res 1994; 22: 3549-3550.
21. Jansson T et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995; 13: 2745-2751.
22. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-1034.
23. Kressner U. Prognostic markers in colorectal cancer: aspects of proliferation, tumour stroma and genetic changes [Dissertation from the Faculty of Medicine 718.]. Uppsala University: Uppsala, 1997, 60 p.
24. Winter SF et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-4174.
25. Bergqvist M et al. p53 auto-antibodies in non-small cell lung cancer patients, can predict increased life expectancy after radiotherapy. Anticancer Res 1998; 18: 1999-2002.
26. Lee JS et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-1903.
27. Prives C. How loops, beta sheets, and alpha helices help us to understand p53. Cell 1994; 78: 543-546.
28. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8: 1235-1246.
29. Egle A et al. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br J Haematol 1997; 97: 418-428.